Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-hCD70 CAR transduced peripheral blood lymphocytes
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-hCD70 CAR transduced peripheral blood lymphocytes represent an adoptive cell therapy where autologous peripheral blood lymphocytes (PBLs) are genetically engineered to express a Chimeric Antigen Receptor (CAR) specifically targeting the human CD70 antigen. This genetic modification enables the patient's own T cells to recognize and eliminate cancer cells that express CD70, independent of the major histocompatibility complex (MHC). The therapy is under investigation for various CD70-positive malignancies, including renal cell carcinoma, gliomas, multiple myeloma, T-cell lymphoma, and acute myeloid leukemia, aiming to leverage the immune system's power to combat these cancers.
- Other names
- CD70-specific CAR-T cellsCD-70-specific CAR-T cellsCD 70-specific CAR-T cellsCD70 CAR-TCD-70 CAR-TCD 70 CAR-TCAR-T cells against CD70Anti-CD70 cellsAnti-CD-70 cellsAnti-CD 70 cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on Anti-hCD70 CAR transduced peripheral blood lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-hCD70 CAR transduced peripheral blood lymphocytes.